The definition of high-risk CLL скачать в хорошем качестве

The definition of high-risk CLL

Kostas Stamatopoulos, MD, PhD, Center for Research and Technology Hellas, Thessaloniki, Greece, discusses the current definition of high-risk chronic lymphocytic leukemia (CLL) and factors that influence this. First, Dr Stamatopoulos explains that patients with TP53 aberration and unmutated immunoglobulin heavy chain gene (IgHV) are considered high-risk when chemoimmunotherapy is the only available treatment option. Following this, Dr Stamatopoulos explains how novel agents, such as ibrutinib, acalabrutinib and venetoclax, are now available for patients with TP53 mutation and unmutated IgHV, which means that the definition of high-risk CLL is changing, and greatly depends on the available treatment options. To conclude, Dr Stamatopoulos compares continuous therapy with Bruton’s tyrosine kinase (BTK) inhibitors versus fixed duration venetoclax, and how treatment approaches vary for different sub-groups of CLL patients. This interview took place during the 2nd ESH Translational Research Conference on Chronic Lymphocytic Leukemia (ESH CLL), 2022. Explore our dedicated feature on genomic testing in CLL here: http://bit.ly/403y417